Financial Ratios RaySearch Laboratories AB
Stocks
RAY B
SE0000135485
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 213.40 SEK | -3.00% |
|
-5.16% | -6.40% |
| 10/06 | RaySearch Head of Business Development Jenna Styan makes maiden share purchase | FW |
| 05/06 | RaySearch to showcase new particle therapy solutions at PTCOG 64 | FW |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -2.65 | 1.05 | 3.99 | 7.77 | 10.09 | |||||
Return on Total Capital | -3.9 | 1.58 | 6.16 | 12.03 | 15.1 | |||||
Return On Equity % | -7.04 | 3.7 | 11.72 | 25.25 | 24.47 | |||||
Return on Common Equity | -7.04 | 3.7 | 11.72 | 25.25 | 24.47 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 92.15 | 88.74 | 89.57 | 91.65 | 92.42 | |||||
SG&A Margin | 65.8 | 57.03 | 54.59 | 48.34 | 48.37 | |||||
EBITDA Margin % | -5.21 | 8.27 | 16.06 | 24.01 | 26.76 | |||||
EBITA Margin % | -9.94 | 3.62 | 11.97 | 21.11 | 24.52 | |||||
EBIT Margin % | -9.98 | 3.59 | 11.95 | 21.1 | 24.52 | |||||
Income From Continuing Operations Margin % | -7.37 | 2.82 | 7.98 | 17.07 | 16.95 | |||||
Net Income Margin % | -7.37 | 2.82 | 7.98 | 17.07 | 16.95 | |||||
Net Avail. For Common Margin % | -7.37 | 2.82 | 7.98 | 17.07 | 16.95 | |||||
Normalized Net Income Margin | -5.71 | 2.4 | 6.73 | 13.78 | 13.38 | |||||
Levered Free Cash Flow Margin | 4.65 | 15.75 | 17.4 | 18.39 | 6.59 | |||||
Unlevered Free Cash Flow Margin | 5.24 | 16.6 | 18 | 18.86 | 6.95 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.42 | 0.47 | 0.53 | 0.59 | 0.66 | |||||
Fixed Assets Turnover | 1.5 | 1.28 | 1.65 | 2.13 | 2.76 | |||||
Receivables Turnover (Average Receivables) | 2.08 | 2.45 | 2.71 | 2.88 | 2.93 | |||||
Inventory Turnover (Average Inventory) | 2.58 | 4.31 | 9.1 | 9.98 | 6.25 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.05 | 1.02 | 1.19 | 1.4 | 1.7 | |||||
Quick Ratio | 0.94 | 0.91 | 1.12 | 1.32 | 1.58 | |||||
Operating Cash Flow to Current Liabilities | 0.49 | 0.58 | 0.68 | 0.69 | 0.68 | |||||
Days Sales Outstanding (Average Receivables) | 175.8 | 148.81 | 134.67 | 127.19 | 124.72 | |||||
Days Outstanding Inventory (Average Inventory) | 141.59 | 84.69 | 40.09 | 36.68 | 58.39 | |||||
Average Days Payable Outstanding | 175.74 | 167.99 | 118.52 | 146.78 | 119.52 | |||||
Cash Conversion Cycle (Average Days) | 141.65 | 65.51 | 56.24 | 17.09 | 63.59 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 86.46 | 84.51 | 72 | 53.83 | 40.07 | |||||
Total Debt / Total Capital | 46.37 | 45.8 | 41.86 | 34.99 | 28.61 | |||||
LT Debt/Equity | 75.62 | 75.64 | 58.75 | 45.04 | 32.2 | |||||
Long-Term Debt / Total Capital | 40.56 | 40.99 | 34.16 | 29.28 | 22.99 | |||||
Total Liabilities / Total Assets | 62.66 | 64.97 | 62.35 | 58.08 | 50.54 | |||||
EBIT / Interest Expense | -10.6 | 2.64 | 12.6 | 27.98 | 42.26 | |||||
EBITDA / Interest Expense | 3.2 | 11.77 | 24.31 | 40.46 | 55.51 | |||||
(EBITDA - Capex) / Interest Expense | -5.4 | 7.98 | 21.8 | 38.99 | 51.91 | |||||
Total Debt / EBITDA | 29.03 | 4.11 | 2.25 | 1.3 | 0.91 | |||||
Net Debt / EBITDA | 23.73 | 2.92 | 0.79 | 0.03 | -0.03 | |||||
Total Debt / (EBITDA - Capex) | -17.2 | 6.06 | 2.5 | 1.35 | 0.98 | |||||
Net Debt / (EBITDA - Capex) | -14.06 | 4.31 | 0.88 | 0.03 | -0.03 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | -1.53 | 31.48 | 21.16 | 16.62 | 12.78 | |||||
Gross Profit, 1 Yr. Growth % | -2.79 | 26.62 | 22.3 | 19.33 | 13.72 | |||||
EBITDA, 1 Yr. Growth % | -158.73 | -309.81 | 135.46 | 33.39 | 25.73 | |||||
EBITA, 1 Yr. Growth % | -346.36 | -147.86 | 300.75 | 105.05 | 31 | |||||
EBIT, 1 Yr. Growth % | -349.4 | -147.32 | 303.09 | 105.34 | 31.05 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 421.09 | -150.25 | 243.06 | 149.49 | 11.94 | |||||
Net Income, 1 Yr. Growth % | 421.09 | -150.25 | 243.06 | 149.49 | 11.94 | |||||
Normalized Net Income, 1 Yr. Growth % | 805.73 | -155.18 | 240.04 | 138.78 | 9.47 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 421.09 | -149.99 | 244.84 | 149.49 | 11.94 | |||||
Accounts Receivable, 1 Yr. Growth % | 5.52 | 16.77 | 3.55 | 15.91 | 6.54 | |||||
Inventory, 1 Yr. Growth % | 229.21 | -53.02 | -33.86 | 13.95 | 107.55 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 256.88 | -2.62 | -9.04 | -10.8 | -15.08 | |||||
Total Assets, 1 Yr. Growth % | 35.34 | 7.52 | 4.09 | 7.09 | -4.74 | |||||
Tangible Book Value, 1 Yr. Growth % | -39.21 | 31.64 | 47.86 | 60.44 | 29.86 | |||||
Common Equity, 1 Yr. Growth % | -6.49 | 4.59 | 11.88 | 19.24 | 12.39 | |||||
Cash From Operations, 1 Yr. Growth % | -28.16 | 49.8 | 42.19 | 6.43 | -20.24 | |||||
Capital Expenditures, 1 Yr. Growth % | 74.92 | -16.27 | 81.37 | -45.42 | 111.28 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -75.68 | 134.97 | 9.14 | 23.11 | -59.59 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -73.38 | 132.15 | 8.1 | 22.11 | -58.43 | |||||
Dividend Per Share, 1 Yr. Growth % | - | - | - | 328.57 | 33.33 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | -6.98 | 13.79 | 26.21 | 18.87 | 14.68 | |||||
Gross Profit, 2 Yr. CAGR % | -6 | 10.94 | 24.44 | 20.8 | 16.49 | |||||
EBITDA, 2 Yr. CAGR % | -34.32 | 10.72 | 122.27 | 102.56 | 29.49 | |||||
EBITA, 2 Yr. CAGR % | 13.98 | 8.59 | 38.5 | 187.03 | 63.89 | |||||
EBIT, 2 Yr. CAGR % | 14.34 | 8.64 | 38.11 | 188.07 | 64.04 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -3.12 | 61.82 | 31.3 | 192.56 | 67.11 | |||||
Net Income, 2 Yr. CAGR % | -3.12 | 61.82 | 31.3 | 192.56 | 67.11 | |||||
Normalized Net Income, 2 Yr. CAGR % | -3.19 | 123.56 | 36.98 | 184.95 | 61.69 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -3.1 | 61.41 | 31.3 | 193.31 | 67.11 | |||||
Accounts Receivable, 2 Yr. CAGR % | -9.3 | 11 | 9.96 | 9.56 | 11.13 | |||||
Inventory, 2 Yr. CAGR % | 154.7 | 24.37 | -44.25 | -13.19 | 53.64 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 73.53 | 86.42 | -5.88 | -9.92 | -12.96 | |||||
Total Assets, 2 Yr. CAGR % | 17.28 | 20.83 | 5.79 | 5.58 | 1 | |||||
Tangible Book Value, 2 Yr. CAGR % | -32.52 | -18.31 | 39.52 | 54.02 | 44.33 | |||||
Common Equity, 2 Yr. CAGR % | -4.07 | -2.72 | 8.17 | 15.5 | 15.76 | |||||
Cash From Operations, 2 Yr. CAGR % | -13.75 | 3.74 | 38.36 | 23.01 | -7.87 | |||||
Capital Expenditures, 2 Yr. CAGR % | 4.89 | 21.02 | -31.63 | -0.5 | 7.55 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -39.35 | 4.01 | 77.37 | 15.98 | -29.5 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -37.26 | 5.26 | 74.63 | 14.95 | -28.78 | |||||
Dividend Per Share, 2 Yr. CAGR % | - | - | - | - | 139.05 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 0.76 | 4.39 | 16.19 | 22.93 | 16.8 | |||||
Gross Profit, 3 Yr. CAGR % | 1.16 | 3.81 | 14.61 | 22.71 | 18.39 | |||||
EBITDA, 3 Yr. CAGR % | -27.55 | -3.44 | 42.38 | 104.95 | 72.78 | |||||
EBITA, 3 Yr. CAGR % | -2.86 | -14.65 | 67.81 | 57.98 | 120.99 | |||||
EBIT, 3 Yr. CAGR % | -2.74 | -14.79 | 68.19 | 57.77 | 121.55 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | -15.54 | -22.16 | 107.88 | 62.63 | 112.39 | |||||
Net Income, 3 Yr. CAGR % | -15.54 | -22.16 | 107.88 | 62.63 | 112.39 | |||||
Normalized Net Income, 3 Yr. CAGR % | -13.53 | -19.73 | 157.1 | 64.85 | 107.15 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -15.53 | -22.28 | 107.88 | 62.63 | 112.75 | |||||
Accounts Receivable, 3 Yr. CAGR % | -9.72 | -1.34 | 8.46 | 11.91 | 8.54 | |||||
Inventory, 3 Yr. CAGR % | 46.1 | 44.99 | 0.76 | -29.25 | 16.01 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 92.75 | 43.13 | 46.76 | -7.55 | -11.67 | |||||
Total Assets, 3 Yr. CAGR % | 16.3 | 14.06 | 14.97 | 6.22 | 2.02 | |||||
Tangible Book Value, 3 Yr. CAGR % | -23.35 | -20.64 | -0.44 | 46.17 | 45.5 | |||||
Common Equity, 3 Yr. CAGR % | -0.42 | -2.34 | 1.93 | 11.74 | 14.45 | |||||
Cash From Operations, 3 Yr. CAGR % | 10.1 | 3.68 | 11.21 | 26.77 | 6.47 | |||||
Capital Expenditures, 3 Yr. CAGR % | -10.82 | -2.7 | -6.49 | -36.57 | 28.01 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -21.74 | 17.83 | 13.15 | 57.1 | -18.41 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -17.94 | 17.89 | 13.32 | 55.05 | -18.12 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 3.84 | 7.59 | 10.26 | 9.96 | 15.58 | |||||
Gross Profit, 5 Yr. CAGR % | 3.22 | 6.42 | 9.9 | 10.3 | 15.36 | |||||
EBITDA, 5 Yr. CAGR % | -30.1 | -17.96 | 13.33 | 29.87 | 44.61 | |||||
EBITA, 5 Yr. CAGR % | -19.46 | -29.55 | 11.95 | 38.64 | 66.32 | |||||
EBIT, 5 Yr. CAGR % | -19.4 | -29.66 | 11.91 | 38.7 | 66.6 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | -20.76 | -27.37 | 0.76 | 32.19 | 90.5 | |||||
Net Income, 5 Yr. CAGR % | -20.76 | -27.37 | 0.76 | 32.19 | 90.5 | |||||
Normalized Net Income, 5 Yr. CAGR % | -21.6 | -26.98 | 3.94 | 33.24 | 113.56 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | -20.76 | -27.44 | 0.77 | 32.2 | 90.5 | |||||
Accounts Receivable, 5 Yr. CAGR % | 2.35 | -2.17 | -2.31 | 2.89 | 9.52 | |||||
Inventory, 5 Yr. CAGR % | - | 235.8 | -0.63 | 18.1 | 19.28 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 79.6 | 78.21 | 44.7 | 18.93 | 19.09 | |||||
Total Assets, 5 Yr. CAGR % | 19.38 | 15.44 | 12.05 | 10.59 | 9.17 | |||||
Tangible Book Value, 5 Yr. CAGR % | -10.28 | -11.69 | -6.07 | 3.47 | 15.5 | |||||
Common Equity, 5 Yr. CAGR % | 7.13 | 2.51 | 2.26 | 4.44 | 7.25 | |||||
Cash From Operations, 5 Yr. CAGR % | 14.53 | 19.33 | 20.63 | 8.67 | 3.14 | |||||
Capital Expenditures, 5 Yr. CAGR % | 82.87 | 31.55 | -19.81 | -22.44 | -1.11 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | -1.7 | 36.07 | 23.34 | 21.97 | -6.34 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 1.26 | 38.85 | 24.75 | 21.34 | -5.87 |
- Stock Market
- Stocks
- RAY B Stock
- Financials RaySearch Laboratories AB
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















